Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Statement re Possible Offer

31 Jan 2008 11:56

Angle PLC31 January 2008 Not for release, publication or distribution in whole or in part, in or into theUnited States, Canada, Australia, Japan or the Republic of Ireland ANGLE plc ("ANGLE" or the "Company") Statement re. Possible Offer and Rule 2.10 announcement 31 January 2008 The Board of ANGLE confirms that it has received an approach which may or maynot lead to an offer being made for the Company. The Board of ANGLE, which isbeing advised by Collins Stewart Europe Limited, will evaluate the approach onits merits and update shareholders accordingly and also wishes to stress thatthere can be no certainty that this approach will lead to an offer being madefor the Company. A further announcement will be made as and when appropriate. In accordance with Rule 2.10 of the City Code on Takeovers and Mergers, theCompany confirms that it has 27,132,931 ordinary shares of 10 pence each inissue. The ISIN reference for these securities is GB0034330679. Ends Contact: Andrew Newland, Chief Executive + 44 (0) 1483 295 830 ANGLE plc Mark Connelly/ Stewart Wallace + 44 (0) 207 523 8350 Collins Stewart Europe Limited Collins Stewart Europe Limited ("Collins Stewart") which is regulated in theUnited Kingdom by The Financial Services Authority is acting for the Company inrelation to the matters described in this announcement and is not advising anyother person, and accordingly will not be responsible to anyone other than theCompany for providing the protections afforded to customers of Collins Stewartor for providing advice in relation to the matters described in thisannouncement. Dealing disclosure requirements Under the provisions of Rule 8.3 of the City Code on Takeovers and Mergers (the"Code"), if any person is, or becomes, "interested" (directly or indirectly) in1% or more of any class of "relevant securities" of the Company, all "dealings"in any "relevant securities" of the Company (including by means of an option inrespect of, or a derivative referenced to, any such "relevant securities") mustbe publicly disclosed by no later than 3.30pm (London time) on the Londonbusiness day following the date of the relevant transaction. This requirementwill continue until the date on which the offer becomes, or is declared,unconditional as to acceptances, lapses or is otherwise withdrawn or on whichthe "offer period" otherwise ends. If two or more persons act together pursuantto an agreement or understanding, whether formal or informal, to acquire an "interest" in "relevant securities" of the Company, they will be deemed to be asingle person for the purpose of Rule 8.3. Under the provisions of Rule 8.1 of the Code, all "dealings" in "relevantsecurities" of the Company by the Company or by any of its respective "associates", must be disclosed by no later than 12.00 noon (London time) on theLondon business day following the date of the relevant transaction. A disclosure table, giving details of the companies in whose 'relevantsecurities' 'dealings' should be disclosed, and the number of such securities inissue, can be found on the Takeover Panel's website atwww.thetakeoverpanel.org.uk . "Interests in securities" arise, in summary, when a person has long economicexposure, whether conditional or absolute, to changes in price or securities.In particular, a person will be treated as having an "interest" by virtue of theownership or control of securities, or by virtue of any option in respect of, orderivative referenced to, securities. Terms in quotation marks are defined in the Code, which can be found on thePanel's website. If you are in any doubt as to whether or not you are requiredto disclose a "dealing" under Rule 8, you should consult the Panel. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
28th Jul 20227:00 amRNSNovel insight into metastasis in NSCLC patients
20th Jul 20222:33 pmRNSHolding(s) in Company
20th Jul 20227:00 amRNSNEW STUDY OF PARSORTIX SYSTEM IN NSCLC
19th Jul 202210:00 amRNSDirector/PDMR Shareholding
15th Jul 20227:00 amRNSResults of Capital Raise
14th Jul 20225:24 pmRNSRetail Offer via PrimaryBid
14th Jul 20225:23 pmRNSProposed Placing and Retail Offer
8th Jul 20225:30 pmRNSIssue of Equity
29th Jun 20224:35 pmRNSResult of 2022 Annual General Meeting
27th Jun 20227:00 amRNSSpread of breast cancer accelerates during sleep
23rd Jun 20226:24 pmRNSIssue of Equity
22nd Jun 20227:00 amRNSSecured contract from pharma services customer
16th Jun 20227:00 amRNSPredicting immunotherapy response in SCLC
14th Jun 20227:00 amRNSPotential role of invasive cellular protrusions
30th May 20227:00 amRNSPartnership with major United States urology group
27th May 20227:00 amRNSMolecular characterisation of CTCs
25th May 20224:35 pmRNSPrice Monitoring Extension
25th May 202212:30 pmRNSANGLE receives FDA clearance for Parsortix
20th May 20227:00 amRNSProstate Cancer UK funds new study using Parsortix
28th Apr 20227:00 amRNSPreliminary Results
20th Apr 20227:00 amRNSNotice of Preliminary Results and Webcast
14th Apr 20227:00 amRNSPoster on Parsortix system presented at AACR 2022
1st Apr 20227:00 amRNSIdentifying drug targets in cancer metastasis
29th Mar 20227:00 amRNSRapid information on patient response to therapies
25th Mar 20227:00 amRNSIdentifying therapeutic targets in TNBC patients
15th Mar 20227:00 amRNSUpdate on laboratory accreditation
9th Mar 20224:41 pmRNSSecond Price Monitoring Extn
9th Mar 20224:36 pmRNSPrice Monitoring Extension
2nd Mar 20226:29 pmRNSHolding(s) in Company
18th Feb 20225:13 pmRNSIssue of Equity
21st Jan 20227:00 amRNSPotential in immunotherapy treatment selection
17th Jan 20227:00 amRNSConcordance of Parsortix with tissue biopsy
13th Jan 20227:00 amRNSUpdate on lab accreditation and ovarian study
10th Jan 20227:00 amRNSInsight into drug resistance in NSCLC
22nd Dec 20216:29 pmRNSIssue of Equity
1st Dec 20216:11 pmRNSIssue of Equity
1st Dec 20217:00 amRNSParsortix in RNA analysis of CTCs as tool in NSCLC
26th Nov 20215:33 pmRNSIssue of Equity
17th Nov 202110:32 amRNSIssue of Equity
15th Nov 20217:00 amRNSIssue of LTIP Options and Share Options
15th Nov 20217:00 amRNSAppointment of Chief Medical Officer
12th Nov 20215:51 pmRNSIssue of Equity
12th Nov 20217:00 amRNSParticipation at Jefferies healthcare conference
11th Nov 20217:00 amRNSParsortix system showcased at NCRI Festival
10th Nov 20215:40 pmRNSIssue of Equity
2nd Nov 20217:00 amRNSChange of Adviser
21st Oct 20215:25 pmRNSIssue of Equity
15th Oct 20215:45 pmRNSIssue of Equity
30th Sep 20214:02 pmRNSIssue of Equity
30th Sep 20217:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.